Literature DB >> 31835012

Opioid Prescribing Among Adults With Disabilities in the United States After the 2014 Federal Hydrocodone Rescheduling Regulation.

Victor Liaw1, Yong-Fang Kuo2,3,4,5, Mukaila A Raji2,3, Jacques Baillargeon3,4,5.   

Abstract

OBJECTIVES: Deaths from prescription opioid overdoses have reached an epidemic level in the United States, particularly among persons with disabilities. The 2014 federal rescheduling regulation is associated with reduced opioid prescribing in the general US population; however, to date, no data have been published on this regulation's effect on persons with disabilities. We examined whether the 2014 hydrocodone rescheduling change was associated with reduced opioid prescribing among adult Medicare beneficiaries with disabilities.
METHODS: We identified 680 876 Medicare beneficiaries with disabilities aged 21-64 in 2013 and 657 687 in 2015 from a 20% national sample. We examined changes in the monthly opioid-prescribing rates from January 1, 2013, through December 31, 2015. We also compared opioid-prescribing rates in 2013 with rates in 2015.
RESULTS: In 2014, the percentage of Medicare beneficiaries with disabilities who received hydrocodone prescriptions decreased by 0.154% per month (95% confidence interval [CI], -0.186 to -0.121, P < .001). The percentage of Medicare beneficiaries with disabilities who received hydrocodone prescriptions decreased from 32.2% in 2013 to 27.7% in 2015, whereas rates of any opioid prescribing, prolonged prescribing (≥90-day supply), and high-dose prescribing (≥100 morphine milligram equivalents per day for >30 days) decreased only modestly, from 50.2% to 49.0%, from 27.4% to 26.5%, and from 7.5% to 7.0%, respectively.
CONCLUSIONS: The 2014 federal rescheduling of hydrocodone was associated with only minor changes in overall and potentially high-risk opioid-prescribing rates. Neither state variation in long-term prescribing nor beneficiary characteristics explained the changes in persistently high opioid-prescribing rates among adults with disabilities after the 2014 regulation. Future studies should examine patient and provider characteristics underlying the persistent high-risk prescribing patterns in this population.

Entities:  

Keywords:  Medicare; disability; hydrocodone; opioid; regulation

Mesh:

Substances:

Year:  2020        PMID: 31835012      PMCID: PMC7119258          DOI: 10.1177/0033354919892638

Source DB:  PubMed          Journal:  Public Health Rep        ISSN: 0033-3549            Impact factor:   2.792


  35 in total

1.  The effect of state laws designed to prevent nonmedical prescription opioid use on overdose deaths and treatment.

Authors:  Ioana Popovici; Johanna Catherine Maclean; Bushra Hijazi; Sharmini Radakrishnan
Journal:  Health Econ       Date:  2017-07-18       Impact factor: 3.046

2.  Decline in opioid prescribing after federal rescheduling of hydrocodone products.

Authors:  Mukaila A Raji; Yong-Fang Kuo; Deepak Adhikari; Jacques Baillargeon; James S Goodwin
Journal:  Pharmacoepidemiol Drug Saf       Date:  2017-12-21       Impact factor: 2.890

3.  Opioid Overdose Hospitalizations among Medicare-Disability Beneficiaries.

Authors:  Jillian L Peters; Wesley M Durand; Kristina A Monteiro; Luba Dumenco; Paul George
Journal:  J Am Board Fam Med       Date:  2018 Nov-Dec       Impact factor: 2.657

4.  Prescription opioid use among disabled Medicare beneficiaries: intensity, trends, and regional variation.

Authors:  Nancy E Morden; Jeffrey C Munson; Carrie H Colla; Jonathan S Skinner; Julie P W Bynum; Weiping Zhou; Ellen Meara
Journal:  Med Care       Date:  2014-09       Impact factor: 2.983

5.  Association between opioid prescribing patterns and opioid overdose-related deaths.

Authors:  Amy S B Bohnert; Marcia Valenstein; Matthew J Bair; Dara Ganoczy; John F McCarthy; Mark A Ilgen; Frederic C Blow
Journal:  JAMA       Date:  2011-04-06       Impact factor: 56.272

6.  Trends in long-term opioid therapy for chronic non-cancer pain.

Authors:  Denise Boudreau; Michael Von Korff; Carolyn M Rutter; Kathleen Saunders; G Thomas Ray; Mark D Sullivan; Cynthia I Campbell; Joseph O Merrill; Michael J Silverberg; Caleb Banta-Green; Constance Weisner
Journal:  Pharmacoepidemiol Drug Saf       Date:  2009-12       Impact factor: 2.890

7.  State Legal Restrictions and Prescription-Opioid Use among Disabled Adults.

Authors:  Ellen Meara; Jill R Horwitz; Wilson Powell; Lynn McClelland; Weiping Zhou; A James O'Malley; Nancy E Morden
Journal:  N Engl J Med       Date:  2016-06-22       Impact factor: 91.245

8.  The Prevalence and Cost of Medicare Beneficiaries Diagnosed and At Risk for Opioid Abuse, Dependence, and Poisoning.

Authors:  Carl L Roland; Xiangyang Ye; Vanessa Stevens; Gary M Oderda
Journal:  J Manag Care Spec Pharm       Date:  2019-01

9.  Trends in opioid use in commercially insured and Medicare Advantage populations in 2007-16: retrospective cohort study.

Authors:  Molly Moore Jeffery; W Michael Hooten; Henry J Henk; M Fernanda Bellolio; Erik P Hess; Ellen Meara; Joseph S Ross; Nilay D Shah
Journal:  BMJ       Date:  2018-08-01

10.  Decline in drug overdose deaths after state policy changes - Florida, 2010-2012.

Authors:  Hal Johnson; Leonard Paulozzi; Christina Porucznik; Karin Mack; Blake Herter
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2014-07-04       Impact factor: 17.586

View more
  6 in total

Review 1.  Claims-based measures of prescription opioid utilization: A practical guide for researchers.

Authors:  Sara E Heins; Christine Buttorff; Courtney Armstrong; Rosalie Liccardo Pacula
Journal:  Drug Alcohol Depend       Date:  2021-09-22       Impact factor: 4.492

2.  Incident Functional Limitations Among Community-Dwelling Adults Using Opioids: A Retrospective Cohort Study Using a Propensity Analysis with the Health and Retirement Study.

Authors:  Kevin T Pritchard; Brian Downer; Mukaila A Raji; Jacques Baillargeon; Yong-Fang Kuo
Journal:  Drugs Aging       Date:  2022-06-17       Impact factor: 4.271

3.  Opioid and Benzodiazepine Substitutes: Impact on Drug Overdose Mortality in Medicare Population.

Authors:  Yong-Fang Kuo; Victor Liaw; Xiaoying Yu; Mukaila A Raji
Journal:  Am J Med       Date:  2022-03-25       Impact factor: 5.928

4.  Regional and temporal variation in receipt of long-term opioid therapy among older breast, colorectal, lung, and prostate cancer survivors in the United States.

Authors:  Derrick C Gibson; Mukaila A Raji; Jacques G Baillargeon; Yong-Fang Kuo
Journal:  Cancer Med       Date:  2021-01-09       Impact factor: 4.452

5.  National patterns of cessation of prescription opioids among Medicare beneficiaries, 2013-2018.

Authors:  Jordan Westra; Mukaila Raji; Yong-Fang Kuo
Journal:  Medicine (Baltimore)       Date:  2022-08-26       Impact factor: 1.817

6.  Association of Occupational and Physical Therapy With Duration of Prescription Opioid Use After Hip or Knee Arthroplasty: A Retrospective Cohort Study of Medicare Enrollees.

Authors:  Kevin T Pritchard; Jacques Baillargeon; Mukaila A Raji; Lin-Na Chou; Brian Downer; Yong-Fang Kuo
Journal:  Arch Phys Med Rehabil       Date:  2021-02-19       Impact factor: 4.060

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.